Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Biotransformation of [14C]HSK7653 in Healthy Chinese Males
NCT04540016Phase 1Completed
- Sponsor
- Sichuan Haisco Pharmaceutical Co., Ltd.
- Start
- Nov 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cofrogliptin in type 2 diabetes mellitus (T2DM), sponsored by Sichuan Haisco Pharmaceutical Co., Ltd. Primary endpoints: Percentage of cumulative drug excretion of [14C]HSK7653, Peak concentration and 1 more. Started Nov 2020; status: completed.
02
Drugs
cofrogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04540016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540016.